Biocure Technology（CURE.X）株式概要バイオキュア・テクノロジー社は、その子会社とともに、遺伝子組換えおよびラニビズマブに使用されるバイオ医薬品技術の開発および商業化に従事している。 詳細CURE.X ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬過去5年間の収益は年間25.9%増加しました。 リスク分析キャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( CA$0 )過去1年間で株主の希薄化は大幅に進んだ 株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るCURE.X Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.04該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m6k2016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesBiocure Technology Inc. 競合他社Green River GoldSymbol: CNSX:CCRMarket cap: CA$686.4kSassy GoldSymbol: CNSX:SASYMarket cap: CA$665.5kGo MetalsSymbol: CNSX:GOCOMarket cap: CA$799.8kDiscovery Harbour ResourcesSymbol: TSXV:DHR.HMarket cap: CA$565.3k価格と性能株価の高値、安値、推移の概要Biocure Technology過去の株価現在の株価CA$0.0452週高値CA$0.2452週安値CA$0.025ベータ3.731ヶ月の変化14.29%3ヶ月変化14.29%1年変化-20.00%3年間の変化-87.30%5年間の変化-97.39%IPOからの変化-98.95%最新ニュースBoard Change • May 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 28Biocure Technology Inc., Annual General Meeting, Jul 30, 2025Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canadaお知らせ • Apr 22Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in fundingBiocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.お知らせ • Dec 20Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in fundingBiocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement.Board Change • Sep 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 20+ 1 more updateAtriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.最新情報をもっと見るRecent updatesBoard Change • May 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 28Biocure Technology Inc., Annual General Meeting, Jul 30, 2025Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canadaお知らせ • Apr 22Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in fundingBiocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.お知らせ • Dec 20Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in fundingBiocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement.Board Change • Sep 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 20+ 1 more updateAtriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.お知らせ • Sep 10Biocure Technology Inc. Announces Chief Executive Officer ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee as chief executive officer. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed as CEO. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.お知らせ • Sep 09Biocure Technology Inc. Announces Board of Director ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee from the board of directors. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed to the board of directors. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.Board Change • Jul 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jul 06Biocure Technology Inc. Announces That Berkan Unal Has Resigned from Its Board of DirectorsBiocure Technology Inc. announced that Berkan Unal has resigned from its board of directors. The Company will be seeking suitable candidates to enhance the composition of the board of directors in the future.お知らせ • Feb 01Biocure Technology Inc. announced that it has received CAD 0.2376 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 55,000 shares at an issue price of CAD 4.32 per share for gross proceeds of CAD 237,600 on January 30, 2023. The company holds now 92.10% interest in BPK.お知らせ • Jan 18Biocure Technology Inc. announced that it has received CAD 0.0541 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 12,500 shares at an issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 17, 2023. The company holds now 93.42% interest in BPK.お知らせ • Dec 23Biocure Technology Inc. Announces Danny Joh Resigned from Board of DirectorsBiocure Technology Inc. announced that Danny Joh has resigned from its board of directors. The Company would like to thank Mr. Joh for his contributions to the Company and wish him all the best for the future. The Company will be seeking for a suitable candidate to enhance the composition of the board of director.お知らせ • May 21Biocure Technology Inc., Annual General Meeting, Jul 25, 2022Biocure Technology Inc., Annual General Meeting, Jul 25, 2022.お知らせ • Jul 15Biocure Technology Inc. announced that it has received CAD 1.073044 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 6,706,525 units at a price of CAD 0.16 per unit for gross proceeds of CAD 1,073,044 on July 14, 2021. Each unit comprised of one common share and one share purchase warrant of the company, where each whole warrant entitles the holder to purchase an additional share for a period of two years from closing, at a price of CAD 0.21 per warrant share. The company has also agreed to pay a finder's fee of 8% in cash and 8% in warrants for the proceeds raised by the finders in the transaction. Each finder warrants entitles the holder to purchase an additional share for a period of two years from closing, at a price of CAD 0.21 per warrant share. All finder fees are subject to CSE approval.Executive Departure • Feb 23Independent Director has left the companyOn the 16th of February, Hans Frykman's tenure as Independent Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Hans' name. Hans is the only executive to leave the company over the last 12 months.お知らせ • Feb 17Biocure Technology Inc. Announces Board ChangesBiocure Technology Inc. announced that Mr. Berkan Unal has joined the Board of Directors as an Independent Director, effective immediately. He will replace Mr. Hans Frykman, whom was a valuable asset to the company's board for 3 years. Currently, he is acting and will continue, as the Business Development Director for Biologics, Gene and Cell Therapy of GenScript Biotech.お知らせ • Jan 06Biocure Technology Corp. Enters into MOU with Symbasis GmbHBiocure Technology Corp. announced that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development. The purpose of this MOU is to establish a Joint Venture in Germany under the name "Oncocart" for clinical trials, production and marketing in Europe, (potentially, including other regions of the world) of ROR1-based products for the CAR-T therapy the target indication of which is CLL. The MOU is intended to form the basis of discussions and negotiations between the Parties for the purpose of entering into final agreements without creating any obligation to do so. Both parties agree that this Joint Venture will enable them to bring together an extremely experienced group of experts and professionals, allowing for all phases of the development to advance more effectively.Is New 90 Day High Low • Dec 24New 90-day high: CA$0.20The company is up 3.0% from its price of CA$0.20 on 25 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period.お知らせ • Oct 15Biocure Technology Inc. announced that it expects to receive CAD 0.250142 million in fundingBiocure Technology Inc. (CNSX:CURE) announced a non-brokered private placement of 1,786,725 units at a price of CAD 0.14 per unit for gross proceeds CAD 250,142 on October 14, 2020. Each unit consists of one common share and one share purchase pursuant. Each warrant entitles the holder to purchase an additional share for a period of two years from closing at a price of CAD 0.21 per warrant share. The company has also agreed to pay finder's fees of CAD 3,360 and 24,000 finder warrants for the proceeds raised by the finders. The transaction is expected to close on October 15, 2020. All securities issued in the transaction have a hold period of February 15, 2021.株主還元CURE.XCA Metals and MiningCA 市場7D14.3%6.5%0.4%1Y-20.0%95.3%32.9%株主還元を見る業界別リターン: CURE.X過去 1 年間で95.3 % の収益を上げたCanadian Metals and Mining業界を下回りました。リターン対市場: CURE.Xは、過去 1 年間で32.9 % のリターンを上げたCanadian市場を下回りました。価格変動Is CURE.X's price volatile compared to industry and market?CURE.X volatilityCURE.X Average Weekly Movementn/aMetals and Mining Industry Average Movement11.6%Market Average Movement10.2%10% most volatile stocks in CA Market17.7%10% least volatile stocks in CA Market3.8%安定した株価: CURE.Xの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCURE.Xのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005n/aSimon Chengwww.biocuretech.comバイオキュア・テクノロジー社はその子会社とともに、遺伝子組換えおよびラニビズマブに使用されるバイオ医薬品技術の開発および商業化に従事している。同社は多発性硬化症治療用のインターフェロン-β、加齢に伴う視力低下治療用のラニビズマブ、化学療法効果治療用のフィルグラスチムを開発している。また、がん細胞を識別して破壊するCAR T細胞療法の研究開発にも取り組んでいる。バイオキュア・テクノロジー社は2005年に設立され、カナダのバンクーバーに本社を置いている。もっと見るBiocure Technology Inc. 基礎のまとめBiocure Technology の収益と売上を時価総額と比較するとどうか。CURE.X 基礎統計学時価総額CA$808.28k収益（TTM）-CA$102.86k売上高(TTM)n/a0.0xP/Sレシオ-7.9xPER（株価収益率CURE.X は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CURE.X 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$102.86k収益-CA$102.86k直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0051グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率3.7%CURE.X の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/30 11:20終値2026/05/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biocure Technology Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 28Biocure Technology Inc., Annual General Meeting, Jul 30, 2025Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canada
お知らせ • Apr 22Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in fundingBiocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.
お知らせ • Dec 20Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in fundingBiocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement.
Board Change • Sep 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 20+ 1 more updateAtriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.
Board Change • May 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 28Biocure Technology Inc., Annual General Meeting, Jul 30, 2025Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canada
お知らせ • Apr 22Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in fundingBiocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws.
お知らせ • Dec 20Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in fundingBiocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement.
Board Change • Sep 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 20+ 1 more updateAtriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE) on September 8, 2023. Pursuant to the Transaction, Biocure Technology Inc. will issue common shares in its capital to the shareholders in the capital of Atriva on the basis of a proposed exchange ratio such that, following the closing of the Transaction, on a fully diluted basis, approximately 75% of the securities of the Resulting Issuer will be held by current Atriva securityholders, together with subscribers in a concurrent financing, and approximately 25% of the securities of the Resulting Issuer will be held by current CURE shareholders. the transaction is subject to the completion of satisfactory due diligence, the parties entering into a definitive agreement with respect to the Transaction on or before November 30, 2023, the completion of a private placement by Atriva or CURE and the approval of the shareholders of the Company and Atriva, and the approval of the CSE and other applicable regulatory authorities.
お知らせ • Sep 10Biocure Technology Inc. Announces Chief Executive Officer ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee as chief executive officer. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed as CEO. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.
お知らせ • Sep 09Biocure Technology Inc. Announces Board of Director ChangesBiocure Technology Inc. announced resignation of Sang Mok Lee from the board of directors. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed to the board of directors. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors.
Board Change • Jul 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jul 06Biocure Technology Inc. Announces That Berkan Unal Has Resigned from Its Board of DirectorsBiocure Technology Inc. announced that Berkan Unal has resigned from its board of directors. The Company will be seeking suitable candidates to enhance the composition of the board of directors in the future.
お知らせ • Feb 01Biocure Technology Inc. announced that it has received CAD 0.2376 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 55,000 shares at an issue price of CAD 4.32 per share for gross proceeds of CAD 237,600 on January 30, 2023. The company holds now 92.10% interest in BPK.
お知らせ • Jan 18Biocure Technology Inc. announced that it has received CAD 0.0541 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 12,500 shares at an issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 17, 2023. The company holds now 93.42% interest in BPK.
お知らせ • Dec 23Biocure Technology Inc. Announces Danny Joh Resigned from Board of DirectorsBiocure Technology Inc. announced that Danny Joh has resigned from its board of directors. The Company would like to thank Mr. Joh for his contributions to the Company and wish him all the best for the future. The Company will be seeking for a suitable candidate to enhance the composition of the board of director.
お知らせ • May 21Biocure Technology Inc., Annual General Meeting, Jul 25, 2022Biocure Technology Inc., Annual General Meeting, Jul 25, 2022.
お知らせ • Jul 15Biocure Technology Inc. announced that it has received CAD 1.073044 million in fundingBiocure Technology Inc. announced a non-brokered private placement of 6,706,525 units at a price of CAD 0.16 per unit for gross proceeds of CAD 1,073,044 on July 14, 2021. Each unit comprised of one common share and one share purchase warrant of the company, where each whole warrant entitles the holder to purchase an additional share for a period of two years from closing, at a price of CAD 0.21 per warrant share. The company has also agreed to pay a finder's fee of 8% in cash and 8% in warrants for the proceeds raised by the finders in the transaction. Each finder warrants entitles the holder to purchase an additional share for a period of two years from closing, at a price of CAD 0.21 per warrant share. All finder fees are subject to CSE approval.
Executive Departure • Feb 23Independent Director has left the companyOn the 16th of February, Hans Frykman's tenure as Independent Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Hans' name. Hans is the only executive to leave the company over the last 12 months.
お知らせ • Feb 17Biocure Technology Inc. Announces Board ChangesBiocure Technology Inc. announced that Mr. Berkan Unal has joined the Board of Directors as an Independent Director, effective immediately. He will replace Mr. Hans Frykman, whom was a valuable asset to the company's board for 3 years. Currently, he is acting and will continue, as the Business Development Director for Biologics, Gene and Cell Therapy of GenScript Biotech.
お知らせ • Jan 06Biocure Technology Corp. Enters into MOU with Symbasis GmbHBiocure Technology Corp. announced that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development. The purpose of this MOU is to establish a Joint Venture in Germany under the name "Oncocart" for clinical trials, production and marketing in Europe, (potentially, including other regions of the world) of ROR1-based products for the CAR-T therapy the target indication of which is CLL. The MOU is intended to form the basis of discussions and negotiations between the Parties for the purpose of entering into final agreements without creating any obligation to do so. Both parties agree that this Joint Venture will enable them to bring together an extremely experienced group of experts and professionals, allowing for all phases of the development to advance more effectively.
Is New 90 Day High Low • Dec 24New 90-day high: CA$0.20The company is up 3.0% from its price of CA$0.20 on 25 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period.
お知らせ • Oct 15Biocure Technology Inc. announced that it expects to receive CAD 0.250142 million in fundingBiocure Technology Inc. (CNSX:CURE) announced a non-brokered private placement of 1,786,725 units at a price of CAD 0.14 per unit for gross proceeds CAD 250,142 on October 14, 2020. Each unit consists of one common share and one share purchase pursuant. Each warrant entitles the holder to purchase an additional share for a period of two years from closing at a price of CAD 0.21 per warrant share. The company has also agreed to pay finder's fees of CAD 3,360 and 24,000 finder warrants for the proceeds raised by the finders. The transaction is expected to close on October 15, 2020. All securities issued in the transaction have a hold period of February 15, 2021.
